Concordia International a Canada-based pharmaceutical company, said Wednesday October 11, that its International segment and certain of its products are part of an investigation into new issues in the UK pharmaceutical sector by the UK Competition and Markets Authority (CMA).
The company said the investigation is at an early, information-gathering stage and that the CMA has confirmed that, at this time, it has not reached any conclusions on whether competition law has been infringed.
The company also said that the investigation includes matters that pre-date its ownership of the International segment. Concordia acquired the International segment as a result of its transaction to purchase Amdipharm Mercury Limited, which closed on October 21, 2015.
Full Content: Street Insider
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
